InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,841.47
(
-0.02%
)
US TECH 100
19,676.00
(
0.20%
)
Dow Jones
43,239.05
(
0.37%
)
Brent Oil
74.16
(
-0.09%
)
Bitcoin
67,284.40
(
-0.50%
)
Post# of 3310
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DaveAu

Send PM Follow Ignore
Followers 1
Posts 210
Boards Moderated 0
Alias Born 02/28/2006

DaveAu

Re: guyschmid post# 1584

Tuesday, 01/30/2018 9:42:09 AM

Tuesday, January 30, 2018 9:42:09 AM

Post# of 3310
I think everyone was expecting Merck to take the biggest hit as they have a weak drug and Mavyret has both lower price and shorter treatment period. I don't see why it matters which of the competitors are losing share though.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent ENTA News
More ENTA News
InvestorsHub NewsWire

Unitronix Corp Advances DeFi Innovation with Tokenized Real-World Assets Integration • UTRX • Oct 17, 2024 7:38 AM

Mass Megawatts Commences Solar Energy Sales Efforts • MMMW • Oct 16, 2024 7:45 AM

SANUWAVE Health Announces 1-For-375 Reverse Stock Split • SNWV • Oct 16, 2024 7:40 AM

Future Hospitality Ventures Unveils Bold, New AI-Driven Initiative to Revolutionize the $300 Billion Hospitality Market • NGTF • Oct 16, 2024 7:07 AM

Kona Gold Beverages, Inc. Announces Strategic Progress and Corporate Evolution • KGKG • Oct 15, 2024 9:00 AM

One World Products Secures First Order for Hemp-Based Reusable Containers, Pioneers Renewable Materials for the Automotive Industry • OWPC • Oct 15, 2024 8:35 AM

Start posting your company's news
Only $200 per official company press release!